- Home
- ENB vs PFE Comparison
ENB vs PFE Comparison
Compare ENB & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENB | PFE |
|---|---|---|
| Founded | 1949 | 1849 |
| Country | Canada | United States |
| Employees | 14800 | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5B | 147.6B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | ENB | PFE |
|---|---|---|
| Price | $55.18 | $25.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $65.00 | $29.29 |
| AVG Volume (30 Days) | 2.7M | ★ 30.7M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | 5.13% | ★ 6.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | ★ $62,579,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.22 | N/A |
| P/E Ratio | ★ $21.67 | $53.79 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.80 | $23.11 |
| 52 Week High | $58.45 | $28.75 |
Technical Indicators
Market Signals| Indicator | ENB | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 55.67 |
| Support Level | $54.82 | $25.06 |
| Resistance Level | $56.84 | $25.88 |
| Average True Range (ATR) | 0.75 | 0.41 |
| MACD | -0.02 | 0.12 |
| Stochastic Oscillator | 43.56 | 72.99 |
Price Performance
Historical ComparisonAbout ENB Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the US and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also operates regulated natural gas utilities in the US and Canada, including Canada's largest natural gas distribution company. The firm has a small renewable energy portfolio primarily focused on onshore and offshore wind projects.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.